Publications by authors named "Eva Van Bos"
Article Synopsis
- Lutetium-177 prostate-specific membrane antigen (Lu-PSMA) is a new treatment option for patients with advanced metastatic castration-resistant prostate cancer (mCRPC), and this study aimed to assess the role of circulating tumor DNA (ctDNA) in predicting treatment outcomes.
- In a study involving 57 patients, it was observed that higher levels of ctDNA were linked to shorter progression-free survival (PFS), with a median PFS of 3.84 months and a notable 37.5% of patients achieving a significant decrease in prostate-specific antigen (PSA) levels.
- Genetic changes in the androgen receptor gene and the PI3K signaling pathway were found to correlate with poorer outcomes in Lu-PS
Background: Small cell carcinoma of the prostate is a rare condition with important differences from prostatic adenocarcinoma in terms of clinical and prognostic characteristics. A low prostate-specific antigen and a symptomatic patient, including paraneoplastic symptoms, characterize small cell carcinoma of the prostate. Diagnosis is made on the basis of prostate biopsy, and fluorodeoxyglucose positron emission tomography/computed tomography is often used for staging because up to 60% of patients present with de novo metastatic disease.
View Article and Find Full Text PDF